US8524692B2 - Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof - Google Patents
Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof Download PDFInfo
- Publication number
- US8524692B2 US8524692B2 US13/068,007 US201113068007A US8524692B2 US 8524692 B2 US8524692 B2 US 8524692B2 US 201113068007 A US201113068007 A US 201113068007A US 8524692 B2 US8524692 B2 US 8524692B2
- Authority
- US
- United States
- Prior art keywords
- phosphatidylglycerol
- aqp3
- glycerol
- cells
- corneal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to the fields of ocular biology and treatments. More specifically, the present invention relates to, inter alia, methods for treating corneal disorders.
- the cornea is an avascular, translucent tissue that serves to allow the entry of light into the visual system and to focus the incoming rays of the visible spectrum.
- the outermost layer of the cornea, the stratified squamous epithelium, is integral in maintaining optical clarity and defending against microbial infection.
- the air-tear interface is the most important refracting surface in the ocular visual apparatus, and an irregular corneal epithelial surface results in substantial degradation of optical clarity, as is seen clinically with corneal abrasions, diabetic epitheliopathy, recurrent corneal erosions, dry eye syndrome, neurotrophic keratopathy, Stevens Johnson syndrome, ocular cicatricial pemphigoid, exposure keratopathy, and corneal transplantation, among others.
- Each of these corneal disease processes significantly compromises vision and consumes considerable resources in the United States in terms of work productivity, medical and pharmaceutical costs and quality of life.
- the barrier function of the corneal epithelium serves a crucial role in maintaining ocular health by preventing microbial infection. Following trauma and chemical injuries of the corneal epithelium, the eye is markedly susceptible to infectious keratitis. Following surgical violation of the corneal epithelium, as occurs in cataract surgery, corneal transplantation surgery and refractive surgery [i.e., laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK)], the risk of keratitis increases significantly. For example, keratitis after LASIK surgery was recently reported to occur in 2.66% of operated eyes (2). A tool to stimulate corneal epithelial healing would have a significant impact on visual morbidity from common ocular ailments, would improve visual rehabilitation after trauma and chemical injuries and would make surgical manipulations of the cornea safer and more reliable.
- LASIK laser in situ keratomileusis
- PRK photorefractive keratectomy
- Keratinocytes form the epithelium of the skin, the epidermis. These cells undergo a distinct pattern of differentiation that is essential for the function of the skin as a protective barrier. This pattern is characterized by growth arrest and expression of the mature keratins 1 and 10 in the first differentiated layer of the epidermis, the spinous layer. Early differentiation in the spinous layer is followed by late differentiation in the granular layer accompanied by expression of proteins that are essential for the formation of the cornified envelope and corneocytes. The corneocytes constitute the outer layer of the epidermis, the stratum corneum, and give skin its resistance to mechanical stress (3).
- This program of keratinocyte differentiation can be regulated in vitro by the extracellular calcium concentration, with low calcium concentrations ( ⁇ 90 ⁇ M) promoting a proliferative phenotype and elevated calcium concentrations (>100 ⁇ M) stimulating differentiation (4, 5).
- the effects of extracellular calcium levels are thought to be physiologically relevant, since a calcium gradient (low in the basal layer and progressively higher in suprabasal layers) has also been observed in the epidermis in situ (6-9). Although the mechanism responsible for generation of this calcium gradient is unknown, presumably the extracellular calcium concentration regulates keratinocyte differentiation via activation of the G protein-coupled calcium-sensing receptor (CaSR) expressed in these cells (10-12).
- CaSR G protein-coupled calcium-sensing receptor
- the immature keratin 14 13
- the differentiation markers involucrin, lor
- Phospholipase D hydrolyzes phospholipids, primarily phosphatidylcholine, to generate phosphatidic acid, which can be dephosphorylated by lipid phosphate phosphatases to yield diacylglycerol. Indeed, in several cell systems, phospholipase D activity has been shown to underlie at least a portion of agonist-induced sustained diacylglycerol production (21, 22). Diacylglycerol, in turn, is known to function as a second messenger (23), as is phosphatidic acid itself (24-30) and (31, 32).
- phospholipase D can also, in the presence of primary alcohols, catalyze a transphosphatidylation reaction to generate a phosphatidylalcohol.
- phospholipase D utilizes alcohols such as ethanol and butanol to yield phosphatidylethanol or -butanol (33), even when these alcohols are at low concentration.
- phospholipase D2 PLD2
- AQP3 glycerol channel aquaporin-3
- PG phosphatidylglycerol
- AQP3 may provide glycerol to phospholipase D2 for the production of phosphatidylglycerol via the transphosphatidylation reaction, and this phosphatidylglycerol acts as a novel lipid signaling molecule to regulate early keratinocyte differentiation (36), as well as corneal epithelial cell function. Manipulations that alter the function of this PLD2/AQP3/PG signaling module can inhibit epidermal keratinocyte proliferation.
- stimulating phosphatidylglycerol formation by increasing AQP3 expression decreases the promoter activity of a marker of the proliferative basal layer (keratin 5) and enhances the promoter activity of a marker of differentiation (keratin 10) (35).
- increasing phosphatidylglycerol production by raising the extracellular glycerol concentration also reduces keratinocyte proliferation, and direct provision of phosphatidylglycerol in the form of liposomes also inhibits the growth of rapidly proliferating keratinocytes (35).
- phosphatidylglycerol liposomes normalize keratinocyte function, accelerating growth in slowly proliferating cells and decreasing proliferation in rapidly growing cells.
- this signaling module also functions in corneal epithelial cells to produce phosphatidylglycerol (PG) and alter cell function.
- PKC-_II One enzyme regulated by phosphatidylglycerol is PKC-_II; thus, in human leukemia cells PKC- ⁇ II is activated by nuclear phosphatidylglycerol, and this activation is required for cell cycle progression (47, 48). PKC- ⁇ is also reportedly phosphatidylglycerol-activated (49) and mediates phosphorylation of the actin-binding domain of moesin.
- PKC-P Another possible phosphatidylglycerol responsive protein kinase is “PK-P”, which has been isolated from human spleen (50-52).
- phosphatidylglycerol can be reincorporated into the local membrane microdomains (lipid rafts) to regulate the organization of signaling molecules, such as the EGF receptor. Consistent with this idea, phosphatidic acid and phosphoinositide 3-kinase products have been reported to be concentrated in lipid rafts when platelets are stimulated by thrombin (53). Phosphatidylglycerol may also function by facilitating the interaction and function of membrane proteins, as has been observed in thylakoid membranes of spinach and a cyanobacterium, for which photosystem assembly requires phosphatidylglycerol (54, 55).
- phosphatidylglycerol and diphosphatidylglycerol are known to be important lipids in mitochondria. For instance, phosphatidylglycerol and cardiolipin restore the mitochondrial membrane potential in depleted mitochondria (56).
- the present invention is directed to a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing a pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.
- the present invention provides a method of treating an eye wound in a subject, comprising the steps administering to the eyes of said subject an effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.
- the present invention provides an ocular composition consisting essentially of dioleoylphosphatidylglycerol.
- FIGS. 1A-1D show that different phosphatidylglycerol species effectively inhibit or promote proliferation in rapidly or slowly dividing keratinocytes, respectively.
- Keratinocytes were treated for 24 hours with the indicated concentrations of different phosphatidylglycerol species, prepared via bath sonication of phospholipid in serum-free keratinocyte medium.
- [ 3 H]Thymidine incorporation into DNA was then determined in duplicate and averaged. All data were transformed prior to analyses to improve assumptions of normality and additivity for the models to be used. Experiments were grouped that had different responses to egg phosphatidylglycerol using finite mixture regression models and the flexmix package in R (1).
- This method clusters each experiment by the regression fit between In(CPM) and In(concentration), grouping cultures with similar regression lines in the same cluster.
- the number of clusters was determined using the Bayesian information criterion (BIC).
- BIC Bayesian information criterion
- a mixed model analysis of variance was used, conducted using the Proc Mixed procedure in SAS 9.13, separately for each of the grouped clusters to determine how the different phosphatidylglycerol species affected the relationship between cell proliferation and phosphatidylglycerol concentration.
- the model used for this analysis of variance included phosphatidylglycerol species as a fixed effect that potentially interacted with In(concentration), and random coefficients for each culture/experiment.
- the number of experiments segregating into each cluster are indicated and *p ⁇ 0.05 versus the response to egg phosphatidylglycerol liposomes.
- the egg phosphatidylglycerol used (47) is actually a mixture of different phosphatidylglycerol species composed of various fatty acids, with palmitate (with 16 carbons and no double bonds, i.e. 16:0) and oleate (18:1) most abundant. Based on the idea that phosphatidylglycerol liposomes can normalize keratinocyte function, it was determined the phosphatidylglycerol species that were most effective at inhibiting the growth of rapidly proliferating keratinocytes and stimulating the proliferation of slowly dividing cells. Different PG species were effective in growth inhibition versus promotion.
- Phosphatidylglycerol species containing polyunsaturated fatty acids were most effective at inhibiting rapidly proliferating keratinocytes, whereas the growth promoting effect in slowly dividing keratinocytes was most effectively induced by PG species with monounsaturated fatty acids (with or without saturated fatty acids).
- Palmitoyl, arachidonyl-PG (16:0, 20:4), palmitoyl, linoleoyl-PG (16:0, 18:2), dilinoleoyl-PG (18:2, 18:2) and soy phosphatidylglycerol (a phosphatidylglycerol mixture with a large proportion of polyunsaturated fatty acids) were particularly effective at inhibiting proliferation in rapidly dividing keratinocytes. Palmitoyl, oleoyl-PG (16:0, 18:1) and dioleoyl-PG (18:1, 18:1) were especially effective proproliferative phosphatidylglycerol species. This result indicates that different phosphatidylglycerol species may signal to different effector enzymes to differentially alter keratinocyte growth, with some PG-binding proteins promoting differentiation and others stimulating proliferation.
- FIGS. 2A-2B show wound healing of full-thickness punch biopsies of mouse skin.
- Two full-thickness skin punch biopsies of ⁇ 4 mm were made on the backs of ICR CD-1 mice.
- For each mouse one wound was either ( FIG. 2A ) untreated (left) or treated with 2M glycerol in water (right) or ( FIG. 2B ) treated with phosphate-buffered saline lacking divalent cations (PBS, left) or PBS containing 100 ⁇ g/mL phosphatidylglycerol, prepared as liposomes via bath sonication (right).
- PBS phosphate-buffered saline lacking divalent cations
- PBS phosphate-buffered saline lacking divalent cations
- PBS phosphatidylglycerol
- FIG. 3 shows that glycerol and phosphatidylglycerol liposomes accelerate wound healing of full-thickness punch biopsies of mouse skin in vivo.
- Two full-thickness skin punch biopsies of ⁇ 4 mm were made on the backs of a total of sixteen ICR CD-1 mice (two groups of four male and four female mice).
- For each mouse one wound was either (1) untreated (No Treat) or treated with 2M glycerol in water (Glycerol) or (2) treated with PBS (PBS) or PBS containing 100 ⁇ g/mL PG, prepared as liposomes via bath sonication (PBS+PG).
- PBS PBS
- PBS+PG bath sonication
- FIGS. 4A-4B shows that cell wounding, but not trypsinization, activates phospholipase D (PLD) but decreases phosphatidylglycerol synthesis.
- FIG. 4A [ 3 H]Oleate-prelabeled keratinocytes were treated with 1% ethanol immediately prior to removal of the cells from the substratum with a cell lifter or trypsinization (with 0.25% trypsin) and incubation for 15 minutes. Reactions were terminated by the addition of 0.2% SDS containing 5 mM EDTA, and [ 3 H]phosphatidylethanol was extracted, separated by thin-layer chromatography and quantified.
- FIG. 4B Cells were treated with [ 14 C]glycerol immediately prior to cell lifting and incubation for 15 minutes. Reactions were terminated by the addition of 0.2% SDS containing 5 mM EDTA, and [ 14 C]PG was extracted, separated by thin-layer chromatography and quantified. Values are expressed as -fold over the control and represent the means ( ⁇ SEM) of 3 separate experiments performed in duplicate; *p ⁇ 0.01. **p ⁇ 0.001 versus the control value; ⁇ p ⁇ 0.001 versus trysinization. In both cases, similar results were obtained when cells were more gently lifted from the dish using a rubber policeman.
- FIG. 5 shows that glycerol and an elevated extracellular calcium concentration act together to inhibit DNA synthesis in proliferating human corneal epithelial cells.
- SV40-immortalized human corneal epithelial cells at approximately 50-60% confluence were treated for 24 hours with dKSF medium containing no calcium supplementation (Control; 90 ⁇ M calcium) or supplemented with 1 mM calcium (1 mM Ca 2+ ) in the presence and absence of the indicated concentrations of glycerol.
- [ 3 H]Thymidine incorporation into DNA was then determined. Values represent the means ⁇ SEM of 3 separate experiments performed in duplicate; *p ⁇ 0.05, **p ⁇ 0.01 versus the control value.
- FIG. 6 shows that liposomes composed of egg phosphatidylglycerol (a mixture of phosphatidylglycerol species with different fatty acid compositions) inhibit DNA synthesis in proliferating human corneal epithelial cells.
- SV40-immortalized human corneal epithelial cells were cultured in a 1:1 mixture of defined keratinocyte serum free (dKSF) medium (Gibco) and minimum essential medium (Cellgro) until approximately 70% confluent. These near-confluent cells were then treated for 24 hours with dKSF medium containing the indicated concentrations of phosphatidylglycerol liposomes, prepared via bath sonication of PG in dKSF.
- dKSF defined keratinocyte serum free
- Cellgro minimum essential medium
- FIGS. 7A-7B show the effect of glycerol on wound closure in transformed human corneal epithelial cells.
- SV40-immortalized human corneal epithelial cells were cultured in a 1:1 mixture of defined keratinocyte serum free (dKSF) medium (Gibco) and minimum essential medium (Cellgro) until confluent. A pipet tip was then used to create a scratch wound in the confluent monolayer. Cells were rinsed with PBS to remove unattached and damaged cells and photographed under the microscope. The medium was replaced with dKSF containing the indicated additions (Ca corresponds to 1 mM Ca 2+ ). Cells were incubated for 24 hours and photographed again.
- dKSF defined keratinocyte serum free
- Gibco defined keratinocyte serum free
- Cellgro minimum essential medium
- FIGS. 8A-8B show the effect of egg phosphatidylglycerol and dioleoylphosphatidylglycerol on wound closure in transformed human corneal epithelial cells.
- SV40-immortalized human corneal epithelial cells were cultured in a 1:1 mixture of defined keratinocyte serum free (dKSF) medium (Gibco) and minimum essential medium (Cellgro) until confluent. A pipet tip was then used to create a scratch wound in the confluent monolayer. Cells were rinsed with PBS to remove unattached and damaged cells and photographed under the microscope.
- dKSF defined keratinocyte serum free
- Cibco defined keratinocyte serum free
- Cellgro minimum essential medium
- FIG. 9 shows baculovirus-expressed AQP3 and PLD2 coimmunoprecipitate from Sf9 insect cells.
- Sf9 insect cells were infected with baculovirus expressing GST-tagged AQP3 (AQP3-GST) alone or both AQP3-GST and His-tagged PLD2 (PLD2-His) as indicated.
- Sf9 lysates were then immunoprecipitated (IP) with anti-GST antibody or anti-PLD2 antibody and the immunoprecipitates analyzed by immunoblotting (IB) using antibodies recognizing GST or His as indicated. A 1/10 volume of lysate was similarly analyzed.
- IP immunoprecipitated
- IB immunoblotting
- the term “a” or “an”, when used in conjunction with the term “comprising” in the claims and/or the specification, may refer to “one”, but it is also consistent with the meaning of “one or more”, “at least one”, and “one or more than one”. Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and/or methods of the invention. It is contemplated that any device or method described herein can be implemented with respect to any other device or method described herein.
- the term “or” in the claims refers to “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or”.
- the term “contacting” refers to any suitable method of bringing a compound or a composition into contact with a cell. In vitro or ex vivo this is achieved by exposing the cell to the compound or agent in a suitable medium. For in vivo applications, any known method of administration is suitable as described herein.
- the term “subject” refers to any human or non-human recipient of the composition described herein.
- the present invention is directed to a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing a pharmaceutically effective amount of dioleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.
- corneal disorders include but are not limited to a corneal ulcer, a corneal erosion, keratitis or dry eye.
- the composition may be administered in a dosage form of an eye drop.
- the dioleoylphosphatidylglycerol is contained in said composition in a concentration of from about 10 ⁇ g/mL to about 1000 ⁇ g/mL (or 0.001% to 0.1%).
- compositions include a surface active agent, a protein, and/or a carrier liquid.
- the composition further comprises one or both of an antibiotic agent and an anti-inflammatory agent.
- the corneal disorder is subsequent to mechanical injury resulting from laser in situ keratomeliusis or photorefractive keratectomy.
- the composition may take any form as is well known to one having ordinary skill in this art including but not limited to a capsule, a bead, a liposome, a sphere, a dissolvable biocompatible polymer sheet, and combinations thereof.
- the present invention is further directed to a method of treating an eye wound in a subject, comprising the step of administering to the eyes of said subject an effective amount of dioleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.
- Any pharmaceutically acceptable carrier known to one having ordinary skill in this art may be used, including water.
- this method reduces contact lens intolerance. Adjusting the dose of dioleoylphosphatidylglycerol is well within the ability of one having ordinary skill in this art and will likely depend on the actual disorder or injury being treated but an effective amount will typically fall within the range of 10 ⁇ g/mL to 1000 ⁇ g/mL (or 0.001% to 0.1%).
- the administration is topical administration to the ocular surface of the eyes.
- topical administration include administration via a carrier vehicle selected from the group consisting of drops of liquid, liquid wash, gels, ointments, sprays and liposomes.
- the topical administration is infusion of said dioleoylphosphatidylglycerol to said ocular surface via a device selected from the group consisting of a pump-catheter system, a continuous or selective release device, and a contact lens.
- the present invention is further directed to an ocular composition consisting essentially of dioleoylphosphatidylglycerol.
- a representative composition is a liposomal composition, types of which are very well known in the art.
- Specific methods used include measurement of PLD activity and phosphatidylglycerol synthesis (46, 62, 66); co-immunoprecipitation and Western blot analysis of AQP3 and PLD2 (34); sucrose density ultracentrifugation of membrane fractions (34), PCR and RT-PCR amplification and cloning.
- SV40-immortalized human corneal epithelial cells were obtained from Dr. Fu-Shin Yu (Wayne State University, Detroit, Mich.). The cells are cultured in defined keratinocyte serum-free (dKSF) medium (Gibco) and passaged following trypsinization from the culture dish. Experiments are performed in dKSF medium (90 ⁇ M calcium) supplemented with the agents of interest (phosphatidylglycerol liposomes, glycerol, elevated extracellular calcium concentration, etc.).
- dKSF defined keratinocyte serum-free
- Membrane Microdomain Isolation Membrane microdomains are isolated by fractionation on sucrose gradients following cell lysis by sodium carbonate, as in (34), and the fractions analyzed by immunoblotting.
- PLD Activity Assay PLD activity is measured by examining the production of [ 3 H]phosphatidic acid and phosphatidylethanol, in the presence of 0.5% ethanol in [ 3 H]oleate-labeled cells, as described in (66, 96), or in non-labeled cells upon addition of [ 3 H] or [ 14 C]glycerol as in (35, 46).
- Corneal Wound Healing Assay Rabbits (4-5 kg) are anesthetized with ketamine/xylazine and corneal wounds made by centrally applying 6 mm filters soaked in n-haptanol for 1 minute, followed by thorough irrigation of the eye with saline to remove the corneal epithelium. Agents of interest in sterile saline is applied to the eye three times per day and wound healing followed by staining with fluorescein (1% sodium fluorescein), digital photography under filtered green light and computerized image analysis twice a day, as in (79).
- fluorescein 1% sodium fluorescein
- glycerol and phosphatidylglycerol liposomes to decrease corneal epithelial cell proliferation, (b) whether PLD2 and AQP3 colocalize in caveolin-rich membrane microdomains in corneal epithelial cells and (c) the ability of regulators of corneal epithelial cell function (e.g., extracellular calcium concentration) to stimulate phosphatidylglycerol production is determined.
- Phosphatidylglycerol can accelerate epidermal wound healing in a mouse model in vivo. In AQP3 knockout mice, both epidermal and corneal wound healing is delayed, suggesting a common mechanism of action, which is possibly related to the lack of phosphatidylglycerol production in the AQP3-deficient epithelia. Because phosphatidylglycerol also accelerates corneal wound healing in vitro, it can be a safe and effective treatment for corneal wounds to hasten healing following trauma, infection or ophthalmic surgery.
- Epidermal keratinocytes express the PLD isoform, PLD2, and this isoform contributes a large proportion of the measured basal PLD activity in these cells.
- PLD2 Epidermal keratinocytes express the PLD isoform, PLD2, and this isoform contributes a large proportion of the measured basal PLD activity in these cells.
- results indicating the ability of PLD to utilize glycerol to synthesize phosphatidylglycerol in vitro and in intact keratinocytes (ii) data suggesting the colocalization of PLD2 and the glycerol channel, AQP3, in epidermal keratinocytes, (iii) data supporting the involvement of AQP3 in the PLD2-mediated generation of the novel signaling molecule phosphatidylglycerol, (iv) results consistent with a role for AQP3, glycerol and phosphatidylglycerol in mediating keratinocyte differentiation, the present
- the PLD2/AQP3/PG signaling module may regulate corneal epithelial cells, indicating that this novel signaling module is not limited to epidermal keratinocytes.
- PLD PLD
- primary alcohols to catalyze the transphosphatidylation reaction instead of hydrolysis
- glycerol the more physiological primary alcohol, glycerol, might be the natural substrate for this reaction.
- PLD utilizes glycerol as a primary alcohol for the transphosphatidylation reaction in intact cells and homogenates (63-65). This ability was demonstrated in vitro using PLD2-overexpressing Sf9 membranes (46).
- radiolabeled phosphatidylglycerol levels were stimulated acutely with TPA (46), although this treatment activates PLD as measured by radiolabeled phosphatidylethanol production (46, 66). Since (i) 1,25-dihydroxyvitamin D 3 and TPA decrease PG synthesis, (ii) PLD1, but not PLD2, expression and activity is increased by 1,25-dihydroxyvitamin D 3 (62) and (iii) TPA activates PLD1 to a greater extent than PLD2 (67), radiolabeled PG production upon exposure to glycerol may be a measure of PLD2 activation in keratinocytes. Thus, PLD2 and the glycerol uptake mechanism, AQP3, should be co-localized.
- PLD2 Colocalizes with AQP3 in Caveolin-Rich Membrane Microdomains in Keratinocytes
- PLD2 and AQP3 might be colocalized to provide glycerol to PLD2 for the transphosphatidylation reaction to yield PG.
- PLD2 is known to be located in caveolin-rich membrane microdomains in the human keratinocyte HaCaT cell line (65), whether these two proteins were present in membrane microdomains in primary mouse keratinocytes was examined. Indeed, sucrose density ultracentrifugation with western blot analysis of each fraction demonstrated that both PLD2 and AQP3 are found in the light membrane fractions also enriched in caveolin-1 (34). Colocalization was further shown by co-immunoprecipitation studies of vesicle populations and by confocal immunocytochemistry.
- the aquaporins are a family of water and water/glycerol channels (37, 38).
- AQP3 is an aquaglyceroporin that transports glycerol efficiently but only weakly transports water (39) and is expressed in the basal layer (40), as well as suprabasal cells (41), of the epidermis.
- An AQP3 null mutant mouse has an abnormal epidermal phenotype, with dry skin, a reduced hydration capacity (43), delayed barrier recovery and wound healing and decreased elasticity, as well as a reduced epidermal glycerol content (44). These abnormalities were corrected by topical or oral application of glycerol but not related analogs (45).
- PLD2 and AQP3 comprise a functional unit in that the aquaglyceroporin provides glycerol for use by PLD2 to produce phosphatidylglycerol.
- Glycerol but not Xylitol or Sorbitol, and PG Liposomes Inhibit Keratinocyte DNA Synthesis
- AQP3 and PLD2 may colocalize to provide glycerol for use by PLD2 in the transphosphatidylation reaction to generate phosphatidylglycerol, which then acts to promote early keratinocyte differentiation.
- This idea would predict that increasing the delivery of glycerol through the AQP3 channel or direct provision of phosphatidylglycerol itself should also trigger early differentiation. Since one of the first hallmarks of early differentiation is growth arrest and a reduction in DNA synthesis, the effect of exogenous glycerol (to enhance flux through the channel) on [3H]thymidine incorporation into DNA, a measure of DNA synthesis, was examined.
- osmotic stress is known to regulate keratinocyte function (70)
- to control for any osmotic effects of glycerol we also used equivalent concentrations of two other osmolytes, xylitol and sorbitol, as controls.
- Glycerol at concentrations from 0.1 to 1% inhibited DNA synthesis and enhanced the inhibitory effect of elevated [Ca 2+ ] e , but similar concentrations of xylitol or sorbitol had little or no effect (35).
- phosphatidylglycerol liposomes inhibit DNA synthesis. Moreover, this effect is not likely to represent toxicity since morphologic changes characteristic of cell death were not observed.
- keratinocytes were treated with liposomes formed from dioleoyl-phosphatidylpropranol (PP) and [3H]thymidine incorporation into DNA measured.
- PP dioleoyl-phosphatidylpropranol
- phosphatidylpropanol liposomes have no effect on this parameter.
- the egg phosphatidylglycerol used in these experiments is composed primarily of the dioleoyl and dipalmitoyl species; therefore, that there is no effect of dipalmitoyl-PP on DNA synthesis was also determined.
- AQP3 knockout mice exhibit delayed wound healing (44).
- the present invention discloses that a mechanism underlying the slower wound healing in this mouse model is the lack of generation of the PG lipid signal.
- increasing the levels of PG might accelerate wound healing in normal epidermis.
- two full-thickness skin punch biopsies on either flank of two groups of mice were made. For one group the wounds were not treated or were treated with 2 M glycerol (in water as a positive control); for the other group the wounds were treated with either phosphate-buffered saline lacking divalent cations (PBS) or 100_g/mL phosphatidylglycerol liposomes in PBS. Wound healing was followed over four days using digital photography and computer image analysis.
- PBS phosphate-buffered saline lacking divalent cations
- FIGS. 2A-2B show a representative mouse from each group and FIG. 3 represents the cumulative results from eight mice per group, expressed as the percent of wound healing at day 4 relative to day 1 (to control for possible slight differences in the size of the initial wounds).
- PG liposomes significantly increased the rate of wound healing.
- the effect of such cell wounding on PLD activity was determined, as monitored by changes in radiolabeled phosphatidylethanol levels in [3H]oleate-prelabeled cells scraped or lifted from the dish in the presence of 0.5% ethanol.
- Controls included cells exposed to ethanol without scraping or lifting as well as cells released from the dish by trypsinization.
- the concentration of 100 ⁇ g/mL phosphatidylglycerol used in the wound healing experiments is roughly equivalent to a concentration of 100 ⁇ M, which is approximately 10,000-fold less than the 2 M glycerol concentration that yielded an essentially equal acceleration of wound healing in skin in vivo.
- PLD2/AQP3/PG signaling module may be critically important in the early differentiative response of keratinocytes to elevated [Ca 2+ ] e : (i) increased PLD activity is associated with induction of differentiation by other agents (66, 74); (ii) PLD2 is co-localized with AQP3 in lipid rafts (34), and these two proteins likely function in combination to increase phosphatidylglycerol formation (46), (ii) altering signal generation by the module by (a) overexpressing AQP3, (b) increasing glycerol influx or (c) providing phosphatidylglycerol directly alters early keratinocyte differentiation (35) and (iv) phosphatidylglycerol liposomes accelerate epidermal wound healing.
- the present invention discloses that this module and the resultant phosphatidylglycerol lipid signal are important in regulating corneal epithelial cell proliferation/differentiation as well.
- the present invention discloses that phosphatidylglycerol liposomes composed of some species (e.g., dioleoyl-phosphatidylglycerol) but not others (the mixture of phosphatidylglycerol species found in egg PG) can accelerate scratch wound healing of corneal epithelial cells in vitro.
- Transformed human corneal epithelial transformed human corneal epithelial cells were cultured in defined keratinocyte serum-free (dKSF) medium (Gibco). Sucrose gradient ultracentrifugation, immunoprecipitation and western blot analysis was used to detect the distribution and colocalization of PLD2 and AQP3 in the gradient fractions.
- DNA synthesis measured as incorporation of [ 3 H]thymidine into DNA, was used as an index of cell proliferation.
- a wound closure assay was used to detect the effect of 0.1% or 0.5% glycerol, Ca plus 0.1% or 0.5% glycerol, egg phosphatidylglycerol, and DOPG on migration (and proliferation) of corneal epithelial cells. Confluent monolayers were scratched with a pipet tip and monitored over time for decreased width of the wound.
- FIGS. 7A and 7B shows the effect of glycerol on wound closure in transformed human corneal epithelial cells. As shown in FIG. 7B , 0.05% glycerol and calcium significantly enhanced wound closure in transformed human corneal epithelial cells.
- FIGS. 8A-8B show the effect of egg phosphatidylglycerol and dioleoylphosphatidylglycerol on wound closure in transformed human corneal epithelial cells.
- 50 mg/ml of dioleoylphosphatidylglycerol significantly enhanced wound closure in transformed human corneal epithelial cells.
- egg phosphatidylglycerol inhibited wound closure, clearly demonstrating the importance of the phosphatidylglycerol species in determining the effect on human corneal epithelial cell migration and wound healing.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- 1. Whitcher et al. 200. Bulletin of the WHO 79:214-221
- 2. Moshirfar et al. 2007. J Cataract Refract Surg 33:474-483
- 3. Bollag et al. 2004. Drug mNews Perspect 17:117-126
- 4. Yuspa et al. 1989 J Cell Biol 109:1207-1217
- 5. Bikle et al. 2001 Mol Cell Endocrinol 177:161-171
- 6. Menon G K, Elias P M 1991 Arch Dermatol 127:57-63
- 7. Menon et al. 1992 Cell Tissue Res 270:503-512
- 8. Menon et al. 1985 J Invest Dermatol 84:508-512
- 9. Menon et al. 1994 J Invest Dermatol 102:789-795
- 10. Oda et al. 2000 J Biol Chem 275:1183-1190
- 11. Oda et al. 1998 J Biol Chem 273:23344-23352
- 12. Komuves et al. 2002 J Cell Physiol 192:45-54
- 13. Harkin et al. 2004 Br J Ophthalmol 88:1154-1158
- 14. Tong et al. 2006 Invest Ophthalmol Vis Sci 47:1938-1946
- 15. Adhikary et al. 2004. Invest Ophthalmol Vis Sci 45:1080-1087
- 16. Umenishi et al. 1996. DNA Cell Biol 15:475-480
- 17. Hamann et al. 1998. Am J Physiol 274:C1332-C1345
- 18. Kawakita et al. 2004. Invest Ophthalmol Vis Sci 45:3507-3512
- 19. Lu et al. 2006. Eur J Cell Biol 85:803-811
- 20. Levin M H, Verkman A S 2006 Invest Ophthalmol Vis Sci 47:4365-4372
- 21. Exton J H 1994 Biochim Biophys Acta 1212:26-42
- 22. Nishizuka Y 1995 FASEB J 9:484-496
- 23. Brose N, Rosenmund C 2002 J Cell Sci 115:4399-4411
- 24. Yokozeki et al. 1998 J Neurochem 71:410-417
- 25. Rizzo 1999 J Biol Chem 274:1131-1139
- 26. Rizzo 2000 J Biol Chem 275:23911-23918
- 27. Kam Y, Exton J H 2001 Mol Cell Biol 21:4055-4066
- 28. Ha K S, Exton J H 1993 J Cell Biol 123:1789-1796
- 29. Sergeant et al. 2001 J Biol Chem 276:4737-4746
- 30. Fang et al. 2001 Science 294:1942-1945
- 31. McPhail et al. 1999 Biochim Biophys Acta 1439:277-290
- 32. Jones et al. 1999 Biochim Biophys Acta 1439:229-244
- 33. Liscovitch et al. 2000 Biochem J 345:401-415
- 34. Zheng X, Bollinger Bollag W 2003 J Invest Dermatol 121:1487-1495
- 35. Bollag 2007 J Invest Dermatol; Jun. 28, 2007
- 36. Bollag W B, Zheng X 2005 Phospholipase D and keratinocyte biology. In: Trends in Protein Research. New York: Nova Science Publishers, Inc.; pp 79-118
- 37. Verkman A S, Mitra A K 2000 Am J Physiol Renal Physiol 278:F13-F28
- 38. Borgnia et al. 1999 Annu Rev Biochem 68:425-458
- 39. Yang B, Verkman A S 1997 J Biol Chem 272:16140-16146
- 40. Matsuzaki et al. 1999 J Histochem Cytochem 47:1275-1286
- 41. Sougrat et al. 2002 J Invest Dermatol 118:678-685
- 42. Ma et al. 2000 Proc Natl Acad Sci USA m97:4386-4391
- 43. Ma et al. 2002 J Biol Chem 277:17147-17153
- 44. Hara M, Ma T, Verkman A S 2002 J Biol Chem 277:46616-46621
- 45. Hara M, Verkman A S 2003 Proc Natl Acad Sci USA 100:7360-7365
- 46. Zheng X, Ray S, Bollag W B 2003 Biochim Biophys Acta 1643:25-36
- 47. Murray N R, Fields A P 1998 J Biol Chem 273:11514-11520
- 48. Gökmen-Polar Y, Fields A P 1998 J Biol Chem 273:20261-20266
- 49. Pietromonaco et al. 1998 J Biol Chem 273:7594-7603
- 50. Klemm D J, Elias L 1988 Arch Biochem Biophys 265:506-513
- 51. Klemm D J, Elias L 1988 Exp Hematol 16:855-860
- 52. Klemm D J, Kazim A L, Elias L 1988 Arch Biochem Biophys 265:496-505
- 53. Bodin et al. 2001 Biochemistry 40:15290-15299
- 54. Sato et al. 2000 Proc Natl Acad Sci USA 97:10655-10660
- 55. Kruse et al. 2000 J Biol Chem 275:6509-6514
- 56. Piccotti et al. 2002 J Biol Chem 277:12075-12081
- 57. Lutter et al. 2000 Nature Cell Biol 2:754-756
- 58. Kuwana et al. 2002 Cell 111:331-342
- 59. Zhai et al. Eur J Biochem 268:48-55
- 60. Epand et al. 2002 J Biol Chem 277:32632-32639
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/068,007 US8524692B2 (en) | 2010-04-29 | 2011-04-29 | Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34344910P | 2010-04-29 | 2010-04-29 | |
US13/068,007 US8524692B2 (en) | 2010-04-29 | 2011-04-29 | Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110268787A1 US20110268787A1 (en) | 2011-11-03 |
US8524692B2 true US8524692B2 (en) | 2013-09-03 |
Family
ID=44858425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/068,007 Active US8524692B2 (en) | 2010-04-29 | 2011-04-29 | Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof |
Country Status (1)
Country | Link |
---|---|
US (1) | US8524692B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3445335A4 (en) * | 2016-04-19 | 2020-03-04 | Nanyang Technological University | Subconjuctival depot forming formulations for ocular drug delivery |
US11028141B2 (en) | 2016-11-09 | 2021-06-08 | Baylor College Of Medicine | Therapeutic for the prevention and/or treatment of weight gain and/or diabetes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
US20070026058A1 (en) * | 2004-05-11 | 2007-02-01 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
-
2011
- 2011-04-29 US US13/068,007 patent/US8524692B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
US20070026058A1 (en) * | 2004-05-11 | 2007-02-01 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
Non-Patent Citations (30)
Also Published As
Publication number | Publication date |
---|---|
US20110268787A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qin et al. | Aquaporin-3 in keratinocytes and skin: Its role and interaction with phospholipase D2 | |
Stancevic et al. | Ceramide-rich platforms in transmembrane signaling | |
EP1874337B1 (en) | Galectin for use in the treatment of dry eye syndrome | |
KR102344321B1 (en) | Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease | |
Cautivo et al. | AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue | |
Rosato et al. | Two-pore and TRPML cation channels: regulators of phagocytosis, autophagy and lysosomal exocytosis | |
JP4387101B2 (en) | Use of a retinal cell apoptosis inhibitor for the prevention or treatment of diabetic retinopathy | |
Kannan et al. | Ceramide-induced apoptosis: role of catalase and hepatocyte growth factor | |
EP2900254B1 (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
US8524692B2 (en) | Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof | |
TWI617306B (en) | Pharmaceutical composition and uses thereof | |
US20100166838A1 (en) | Methods And Compositions For Modulating Keratinocyte Function | |
EP1154786B1 (en) | Compositions for altering mucus secretion | |
Yan et al. | VIP induces changes in the F-/G-actin ratio of Schlemm's canal endothelium via LRRK2 transcriptional regulation | |
Dartt et al. | Tears and their secretion | |
Ranty et al. | Ceramide production associated with retinal apoptosis after retinal detachment | |
Choi et al. | Gintonin, a Panax ginseng-derived LPA receptor ligand, attenuates kainic acid-induced seizures and neuronal cell death in the hippocampus via anti-inflammatory and anti-oxidant activities | |
CA2943607A1 (en) | Compositions and methods to treat niemann-pick disease | |
EP3250218B1 (en) | Naktide peptide for treating obesity | |
Ying | Deleterious network hypothesis of apoptosis | |
Lin et al. | Limbal Stem Cell Dysfunction Induced by Severe Dry Eye via Activation of the p38 MAPK Signaling Pathway | |
Bollag¹ et al. | The role of phospholipase D in keratinocyte biology | |
Faude et al. | R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil inhibit human retinal pigment epithelial cell contraction | |
Sepulveda et al. | APOE4 genotype and aging impair injury-induced microglial behavior in brain slices, including toward Aβ, through P2RY12 | |
WO2023279067A1 (en) | Targeting piezo1 to treat inherited and age-related macular degenerations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOLLAG, WENDY;XIE, DING;REEL/FRAME:026400/0756 Effective date: 20110527 |
|
AS | Assignment |
Owner name: GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTIT Free format text: CHANGE OF NAME;ASSIGNOR:MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.;REEL/FRAME:029660/0774 Effective date: 20110604 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:GEORGIA REGENTS UNIVERSITY;REEL/FRAME:040479/0282 Effective date: 20161025 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |